This is the authors' abstract. We don't add key points for this paper.
The aim of this study was to investigate the role of human β -defensin 3 (hBD3) in the initiation stage of atherosclerosis with human umbilical vein endothelial cells (HUVECs) triggered by tumor necrosis factor- (TNF-)α. The effects of hBD3 on TNF- α -induced endothelial injury and inflammatory response were evaluated. Our data revealed that first, hBD3 reduced the production of interleukin-6 (IL-6), IL-8, monocyte chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor (MIF) in HUVECs in a dose-dependent manner. In addition, hBD3 significantly prevented intracellular reactive oxygen species (ROS) production by HUVECs. Second, western blot analysis demonstrated that hBD3 dose-dependently suppressed the protein levels of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in TNF- α -induced HUVECs. As a result, hBD3 inhibited monocyte adhesion to TNF- α -treated endothelial cells. Additionally, hBD3 suppressed TNF- α -induced F-actin reorganization in HUVECs. Third, hBD3 markedly inhibited NF - κ B activation by decreasing the phosphorylation of IKK- α / β , I κ B, and p65 subunit within 30 min. Moreover, the phosphorylation of p38 and c-Jun N-terminal protein kinase (JNK) in the mitogen-activated protein kinase (MAPK) pathway were also inhibited by hBD3 in HUVECs. In conclusion, hBD3 exerts anti-inflammatory and antioxidative effects in endothelial cells in response to TNF- α by inhibiting NF - κ B and MAPK signaling.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bian et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: